Related Experiment Video
Updated: Oct 14, 2025
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
A New Generation of Vaccines in the Age of Immunotherapy
Alfredo Addeo1, Alex Friedlaender1,2, Elisa Giovannetti3,4
1Oncology Department, Undivert Hospital, Geneva, Switzerland.
Purpose Of Review:
Cancer vaccines are one of the most extensively studied immunotherapy type in solid tumors. Despite favorable presuppositions, so far, the use of cancer vaccines has been associated with disappointing results. However, a new generation of vaccines has been developed, promising to revolutionize the immunotherapy field.
Recent Findings:
In this review, we aim to highlight the advances in cancer vaccines and the remaining hurdles to overcome. Cancer vaccination has experienced tremendous progress in the last decade, with myriad promising developments. Future efforts should focus on optimization of target identification, streamlining of most appropriate vaccination strategies, and adjuvant development, as well as predictive biomarker identification. Cautious optimism is warranted in the face of early successes seen in recent clinical trials for oncolytic vaccines. If an approach were to prove successful, it could revolutionize cancer therapy the way ICIs did in the previous decade.
Insights
New cancer vaccines show promise for revolutionizing immunotherapy in solid tumors. Future research focuses on optimizing targets, strategies, and biomarkers for improved cancer treatment outcomes.
Area of Science:
- Immunology
- Oncology
- Vaccinology
Background:
- Cancer vaccines represent a significant area of research within cancer immunotherapy for solid tumors.
- Despite extensive study, historical cancer vaccine applications have yielded disappointing clinical outcomes.
- A new generation of cancer vaccines is emerging with the potential to transform the field.
Purpose of the Study:
- To review recent advancements in cancer vaccine development.
- To identify persistent challenges and future directions in cancer vaccination strategies.
- To assess the potential of novel cancer vaccines in clinical settings.
Main Methods:
- Literature review of recent studies on cancer vaccines and immunotherapies.
- Analysis of clinical trial data and preclinical research findings.
- Synthesis of information on target identification, vaccination strategies, and adjuvant development.
Main Results:
- Significant progress has been made in cancer vaccine technology over the past decade.
- Early clinical trials of oncolytic vaccines demonstrate promising results.
- Key areas for future development include target selection, strategic optimization, adjuvant innovation, and biomarker discovery.
Conclusions:
- Cancer vaccination holds considerable promise for revolutionizing cancer therapy.
- Overcoming current hurdles requires focused efforts in research and development.
- Cautious optimism is justified by emerging successes, potentially mirroring the impact of immune checkpoint inhibitors (ICIs).
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy
01:29Microorganisms in Medicine and Therapeutics
01:51Vaccinations
01:22Development of Immunocompetence
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...